Thermo Fisher Scientific CD66e (CEA) Monoclonal Antibody (CB30), eBioscience

Applications

Tested Dilution

Publications

Western Blot (WB)

1:1,000

View 1 publication 1 publication

Immunohistochemistry (Paraffin) (IHC (P))

1 µg/mL

-

Immunocytochemistry (ICC/IF)

5 µg/mL

-

Flow Cytometry (Flow)

Assay-Dependent

-

Product Specifications

Species Reactivity

Human

Published species

Not Applicable

Host/Isotype

Mouse / IgG1, kappa

Class

Monoclonal

Type

Antibody

Clone

CB30

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

0.5 mg/mL

Purification

Affinity chromatography

Storage buffer

PBS, pH 7.2

Contains

0.09% sodium azide

Storage conditions

4° C

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_2864916

Product Specific Information

Description: The monoclonal antibody CB30 recognizes human CD66e, also known as CEA (carcinoembryonic antigen) and CEACAM5. As a member of the immunoglobulin superfamily, it is large GPI-linked glycosylated protein with a molecular weight about 200 kDa. It is expressed mainly on epithelial cells and on a variety of tumors of the gastrointestinal, respiratory and genitourinary tracts. CD66e has been shown to function in cell adhesion and migration via homophilic and heterophilic interactions with NCA (non-specific cross-reacting antigen also known as CEACAM6 and CD66c). Overexpression is correlated with tumor invasiveness and is therefore used as a clinical marker.

Applications Reported: This CB30 antibody has been reported for use in flow cytometric analysis, immunoblotting (WB), and immunohistochemical staining.

Applications Tested: This CB30 antibody has been tested by immunohistochemistry and by western blot on cell lysates prepared from MCF7 cells. This antibody can be used at less than or equal to 1 µg/mL for immunoblotting and less than 10 µg/mL for IHC. It is recommended that this antibody be carefully titrated for optimal performance in the assay of interest.

Purity: Greater than 90%, as determined by SDS-PAGE.

Aggregation: Less than 10%, as determined by HPLC.

Filtration: 0.2 µm post-manufacturing filtered.

Target Information

CEA (Carcino Embryonic Antigen, CD66e) is synthesized during development in the fetal gut, and re-expressed in increased amounts in intestinal carcinomas and several other tumors. CEA is a member of carcinoembryonic antigens, immunoglobulin supergene family and consists of a single N domain (structural homology to the immunoglobulin variable) and six immunoglobulin constant-like A (A1, A2, A3) and B domains (B1, B2, B3). Antibodies to CEA are useful in identifying the origin of various metastatic adenocarcinomas and in distinguishing pulmonary adenocarcinomas (60 to 70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). CEA is a member of a large family of glycoproteins, a useful tumor marker for adenocarcinoma, and found in adenocarcinomas of endodermally derived digestive system epithelium and fetal colon. Two subgroups of the CEA family, the CEA cell adhesion molecules and the pregnancy-specific glycoproteins, are located within a 1.2 Mb cluster on the long arm of chromosome 19. Eleven pseudogenes of the CEA cell adhesion molecule subgroup are also found in the cluster. CEA was originally described in bile ducts of liver as biliary glycoprotein. Subsequently, CEA was found to be a cell-cell adhesion molecule detected on leukocytes, epithelia, and endothelia. The encoded protein mediates cell adhesion via homophilic as well as heterophilic binding to other proteins of the subgroup. Multiple cellular activities have been attributed to the encoded protein, including roles in the differentiation and arrangement of tissue three-dimensional structure, angiogenesis, apoptosis, tumor suppression, metastasis, and the modulation of innate and adaptive immune responses. Multiple transcript variants encoding different isoforms have been reported, but the full-length nature of all variants has not been defined.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.